Haleon completes demerger from GSK launches as an independent company focused on consumer health

Haleon launches as an independent company 100% focused on consumer health, completing its demerger from GSK. The newly listed business is driven by its purpose to deliver better everyday health with humanity. Trading commenced today on the London Stock Exchange (LSE), with Brian McNamara, CEO of Haleon, leading the opening ceremony to signal the start of trading. Trading on the New York Stock Exchange (NYSE) is set to follow, and a similar market-opening event will take place on Wednesday 20 July 2022. Haleon has a world-class portfolio of brands including Eno, Iodex, Otrivin, Crocin, Sensodyne and Octocalcium and will continue to develop category leading brands that address real consumer health needs, while focusing on future innovation across its entire portfolio. With an increased consumer focus on health and wellness, an ageing global population, an emerging middle class in high-growth economies, growing self-care in the face of increased pressure on public healthcare systems and sizeable unmet consumer needs, Haleon has launched at a time when the consumer healthcare market is set for expansion (expected to be at a rate of 3-4% per annum over the medium-term). Haleon expects to deliver medium-term annual organic revenue growth of 4-6%. Despite huge improvements in medicine, data and technology, everyday health remains elusive for too many people. Haleon aims to change this through a two-pronged approach. First, by working to remove barriers to better everyday health, and second, by aiming to empower 50 million people a year by 2025 to be more included in opportunities for better everyday health. The company

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!